Illumina (ILMN) Receives Coverage Optimism Rating of 0.14
News stories about Illumina (NASDAQ:ILMN) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Illumina earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the life sciences company an impact score of 45.106907098522 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Illumina Inc Rises 8.01% on Heavy Volume: Watch For Potential Pullback (mysmartrend.com)
- 5 Reasons Illumina Enjoyed a Big J.P. Morgan Conference Bounce (finance.yahoo.com)
- Illumina (ILMN) Looks Good: Stock Adds 6.9% in Session (finance.yahoo.com)
- Illumina, Inc. (ILMN) : Consensus Analysts Rating is Good For Investors? – Wall Street Morning (wallstreetmorning.com)
- Illumina, Inc. (NASDAQ:ILMN) – Is The Stock Overvalued? (P/E Analysis) – Nasdaq Journal (press release) (nasdaqjournal.com)
A number of research analysts have weighed in on the stock. BTIG Research assumed coverage on shares of Illumina in a report on Friday, January 5th. They issued a “neutral” rating for the company. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. William Blair cut shares of Illumina from an “outperform” rating to a “market perform” rating in a research note on Friday, January 5th. Evercore ISI began coverage on shares of Illumina in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $250.00 target price for the company. Finally, Piper Jaffray Companies boosted their target price on shares of Illumina to $274.00 and gave the stock an “overweight” rating in a research note on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. Illumina has an average rating of “Buy” and an average price target of $214.38.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s revenue was up 17.6% on a year-over-year basis. During the same period last year, the firm posted $0.97 EPS. research analysts expect that Illumina will post 3.75 earnings per share for the current fiscal year.
In related news, SVP Oene Mark Van sold 1,250 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $207.21, for a total transaction of $259,012.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Charles Dadswell sold 1,609 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $207.88, for a total transaction of $334,478.92. Following the sale, the senior vice president now owns 7,217 shares of the company’s stock, valued at approximately $1,500,269.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 138,921 shares of company stock valued at $29,744,781. 0.89% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Illumina (ILMN) Receives Coverage Optimism Rating of 0.14” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/01/10/illumina-ilmn-receives-coverage-optimism-rating-of-0-14.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.